Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
about
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionAnti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2.Role of HER2 gene overexpression in breast carcinoma.Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.Clinical trial designs for predictive biomarker validation: one size does not fit all.HER2/neu antisense targeting of human breast carcinoma.Herceptin: from the bench to the clinic.Biologic and therapeutic role of HER2 in cancer.Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.Photodynamic tumor eradication with a novel targetable photosensitizer: strong vascular effects and dependence on treatment repetition versus potentiation.Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease.Targeting the function of the HER2 oncogene in human cancer therapeutics.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoIdentification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture.Clinical significance of erbB-2 (HER-2/neu) protein.Growth factors in the gastrointestinal tractA Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen.Two dimensions in targeting HER2.Novel agents in epithelial ovarian cancer.Emerging strategies and applications of pharmacogenomicsExpression of the ERBB3 gene product in breast cancer.Mathematical models of cancer dormancy.The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis.Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogenec-erbB-3: a nuclear protein in mammary epithelial cells.Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancerIsolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.The Basis of OncoimmunologyMonitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs.Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.Structure based antibody-like peptidomimetics.HER2-positive breast cancer: current treatment strategies.
P2860
Q24302462-B99A3EE3-EDD6-4368-B2F4-4C9A89DF08B6Q26824462-22C29B87-1D97-4C63-8776-AB9B80E1C981Q28066285-34F3DA86-3562-4EED-ADEC-B1B62715F280Q30412654-663642F9-9F64-4422-9C6E-2496E0DF5A48Q30530901-B1A96010-14FE-4D9F-A1BD-13D141644CC3Q33810080-045F89A8-2F80-4F33-A8C2-D9CB4204CA3CQ33816185-2E3CFE83-62D7-4D4F-939E-7F8DD912BA8BQ33931164-5E2AFEFF-11DA-4C6B-90CC-3B3181441D93Q34097089-AACD4741-570F-4046-A875-156D6A41F9C4Q34130563-D2CE83DA-D272-42B4-AC08-D64E51802BD6Q34211018-22CC0B92-6A97-4DCC-BFB9-8B2BC349B1B1Q34267775-ABD443DD-9A74-41CB-BCB6-707A686B8CCBQ34348403-B7DA7B29-EF06-4DB3-B1CD-CA2A1417DE68Q34474855-A05B9C30-7E74-404A-814C-2F8AC561B738Q34565743-16B10B52-E02F-4498-B4AA-BC2EBB7D4B9DQ34766486-B44BC8C7-654B-4B7D-9509-183BEB3220EDQ34787422-BF232131-5CF0-44D2-B119-71B6BF3634E1Q35222509-0BFE989F-EA93-43A6-AA24-00EF1E1BBAC4Q35269163-08708847-AEC1-4C3D-AAA0-2FE7F4C833E3Q35271481-78449018-2956-4666-8A4C-204A38ABA2BDQ35871726-20827948-EC7E-4EF1-AA8A-C6C89DF9660FQ35888532-6DC6DBDD-F52F-45E0-BA2A-F67458B0F979Q35895143-03B1074D-5D35-4C25-9B18-3987E52BA94BQ35968752-88FFEA17-9CEE-4C23-AFC3-F8D29DE971D9Q35988130-0270D303-6B3B-49F1-9D25-3839A04E38C9Q35994633-B03FC5A6-FB70-463D-A7A1-2E29E2716A6AQ35994960-76DC1709-D7A7-4D22-9F92-38D1FC6F8800Q36087106-9BCEA552-7F00-4B30-8065-3E7CEBB1AA1DQ36101895-B09484ED-55A4-4C05-8EF9-36AADAEB1FAFQ36230784-99E1E509-8AD6-49BA-B04A-9C60CA7E7FE5Q36325718-69759342-DE0E-4733-9418-35BE2F3D9B2CQ36388489-D6070E1F-84A6-4BBB-BFEA-971685B1F611Q36618907-4875E8CE-8B20-41D0-A21C-8494636964B8Q36678851-C68D1384-6C11-4B8B-A2DB-ABAFFB585B2AQ36680209-0F8DA225-0561-4966-ADBE-7A246D56DF07Q36694110-AF527A40-7302-47CD-8673-114E7BD02FE5Q36814409-058EABA7-7F75-4110-8C62-244E6E21AE63Q36992036-CB905DFB-1FE3-4026-8CEA-8C6FD063E573Q37148681-ED332048-BCB0-419D-9498-06FDD6E4B17AQ37201524-090EB77E-7BD9-459F-8226-CDC4E9D0B7BC
P2860
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@ast
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@en
type
label
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@ast
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@en
prefLabel
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@ast
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@en
P2093
P356
P1476
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
@en
P2093
Mordenti J
Palladino MA Jr
Shepard HM
P2888
P304
P356
10.1007/BF00918679
P577
1991-05-01T00:00:00Z